Expertise in
14
conditions

Dr. Andrew M. Brunner

Oncology
Massachusetts General Hospital
55 Fruit St, 
Boston, MA 
Accepting New Patients
Offers Telehealth
13 Years of Experience
Expertise in
14
conditions
Massachusetts General Hospital
55 Fruit St, 
Boston, MA 

Overview

Andrew Brunner is an Oncologist practicing medicine in Boston, Massachusetts. He has been practicing medicine for over 13 years.

Dr. Brunner is highly rated in 14 conditions, according to our data. His clinical expertise encompasses Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML), Leukemia, Chronic Myelomonocytic Leukemia (CMML), and Bone Marrow Aspiration.

He is actively involved in clinical research, co-authoring 159 peer reviewed articles and participating in 8 clinical trials. Dr. Brunner is currently accepting new patients.

Specialties

Oncology

Licenses

Internal Medicine in MA

Hospital Affiliations

Newton-Wellesley Hospital
Massachusetts General Hospital
North Shore Medical Center -
Brigham And Women's Hospital
Wentworth-Douglass Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
BMC HealthNet
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Mass General Brigham Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

Massachusetts General Hospital
55 Fruit St, Boston, MA 02114

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Phase Ib Study of AZD6738 for Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia Progressing on Front-Line Therapy
A Phase Ib Study of AZD6738 for Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia Progressing on Front-Line Therapy
Enrollment Status: Active_not_recruiting
Publish Date: May 11, 2026
Intervention Type: Drug
Study Drug: AZD6738
Study Phase: Phase 1
TIM3 Inhibition With MBG453 for Patients With Lower Risk MDS: an Adaptive Two-Stage Phase II Clinical Trial
TIM3 Inhibition With MBG453 for Patients With Lower Risk MDS: an Adaptive Two-Stage Phase II Clinical Trial
Enrollment Status: Terminated
Publish Date: February 27, 2026
Intervention Type: Drug
Study Drug: MBG453
Study Phase: Phase 2
A Pilot Proof-of-Concept Study of Talazoparib-Based Therapy for Cohesin-Mutated AML and MDS With Excess Blasts
A Pilot Proof-of-Concept Study of Talazoparib-Based Therapy for Cohesin-Mutated AML and MDS With Excess Blasts
Enrollment Status: Active_not_recruiting
Publish Date: February 25, 2026
Intervention Type: Drug
Study Drug: Talazoparib
Study Phase: Phase 1
Phase I Dose Escalation Study of Velcade in Combination With Lenalidomide in Patients With Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) After Allogeneic Stem Cell Transplantation
Phase I Dose Escalation Study of Velcade in Combination With Lenalidomide in Patients With Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) After Allogeneic Stem Cell Transplantation
Enrollment Status: Completed
Publish Date: January 16, 2026
Intervention Type: Drug
Study Drugs: Lenalidomide, Velcade
Study Phase: Phase 1
A Randomized, Double-blind, Placebo-controlled Phase III Multi-center Study of Azacitidine With or Without MBG453 for the Treatment of Patients With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)
A Randomized, Double-blind, Placebo-controlled Phase III Multi-center Study of Azacitidine With or Without MBG453 for the Treatment of Patients With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)
Enrollment Status: Terminated
Publish Date: January 13, 2026
Intervention Type: Drug
Study Drugs: MBG453, Azacitidine
Study Phase: Phase 3
Phase 2 Study of Mitoxantrone, Etoposide, and Cytarabine (MEC) Plus Lenalidomide for the Treatment of Adult Patients With Relapsed or Refractory Acute Myeloid Leukemia
Phase 2 Study of Mitoxantrone, Etoposide, and Cytarabine (MEC) Plus Lenalidomide for the Treatment of Adult Patients With Relapsed or Refractory Acute Myeloid Leukemia
Enrollment Status: Completed
Publish Date: October 15, 2025
Intervention Type: Drug
Study Drugs: Etoposide, Cytarabine, Lenalidomide, Mitoxantrone
Study Phase: Phase 2
Phase 1b, Multi-arm, Open-label Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
Phase 1b, Multi-arm, Open-label Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
Enrollment Status: Completed
Publish Date: May 18, 2025
Intervention Type: Drug
Study Drugs: Decitabine, PDR001, MBG453, Azacitidine
Study Phase: Phase 1
A Phase I/II Study to Investigate the Safety and Clinical Activity of GSK3326595 and Other Agents in Participants With Myelodysplastic Syndrome and Acute Myeloid Leukaemia
A Phase I/II Study to Investigate the Safety and Clinical Activity of GSK3326595 and Other Agents in Participants With Myelodysplastic Syndrome and Acute Myeloid Leukaemia
Enrollment Status: Terminated
Publish Date: February 06, 2023
Intervention Type: Drug
Study Drugs: GSK3326595, 5-Azacitidine
Study Phase: Phase 1/Phase 2
View 7 Less Clinical Trials

159 Total Publications

Azacitidine-Venetoclax or Induction Chemotherapy for Acute Myeloid Leukemia.
Azacitidine-Venetoclax or Induction Chemotherapy for Acute Myeloid Leukemia.
Journal: The New England journal of medicine
Published: September 02, 2026
Similar Doctors
Expertise in
26
conditions
Expertise in
26
conditions
Referral may be required

Massachusetts General Hospital

55 Fruit St, 
Boston, MA 
 (0.1 miles away)
617-724-4000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jeremy Abramson is an Oncologist practicing medicine in Boston, Massachusetts. Dr. Abramson is highly rated in 26 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, B-Cell Lymphoma, Classical Hodgkin Lymphoma, Bone Marrow Aspiration, and Tissue Biopsy. Dr. Abramson is currently accepting new patients.

Expertise in
30
conditions
Expertise in
30
conditions
Referral may be required

Office

55 Fruit St, 
Boston, MA 
 (0.1 miles away)
617-724-4000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Edwin Choy is an Oncologist practicing medicine in Boston, Massachusetts. Dr. Choy is highly rated in 30 conditions, according to our data. His clinical expertise encompasses Adult Soft Tissue Sarcoma, Liposarcoma, Osteosarcoma, and Synovial Sarcoma. Dr. Choy is currently accepting new patients.

Expertise in
16
conditions
Expertise in
16
conditions
Referral may be required

Dana-Farber Cancer Institute

450 Brookline Ave, 
Boston, MA 
 (2.7 miles away)
877-442-3324
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Matthew Davids is an Oncologist practicing medicine in Boston, Massachusetts. Dr. Davids is highly rated in 16 conditions, according to our data. His clinical expertise encompasses Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), Small Lymphocytic Lymphoma (SLL), Bone Marrow Aspiration, and Tissue Biopsy. Dr. Davids is currently accepting new patients.

Frequently Asked Questions about Dr. Andrew M. Brunner

How do I make an appointment with Dr. Andrew M. Brunner?

You can book an appointment with Dr. Andrew M. Brunner by calling their office at 617-726-2000. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Andrew M. Brunner a top-rated expert for Myelodysplastic Syndrome (MDS)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Andrew M. Brunner is classified as an Elite expert for Myelodysplastic Syndrome (MDS), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Andrew M. Brunner specialize in?

While Dr. Andrew M. Brunner is a Oncology, they have specific expertise in Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML), and Leukemia. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Andrew M. Brunner participate in research or clinical trials?

Yes. Dr. Andrew M. Brunner has published 159 articles and abstracts on conditions like Myelodysplastic Syndrome (MDS). You can view a list of Dr. Andrew M. Brunner's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Andrew M. Brunner accept my insurance?

Dr. Andrew M. Brunner accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 617-726-2000 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Brunner's expertise for a condition
ConditionClose
View All 11 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile